---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report. Covers Cost-effectiveness evidence. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics/cost-effectiveness"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

No cost-effectiveness or budget impact model of claseprubart has been published. Published analyses in CIDP evaluate efgartigimod alfa and immunoglobulin. CDA-AMC estimated an incremental cost-effectiveness ratio for efgartigimod alfa injection of $1,872,111 per QALY gained compared with immunoglobulin, and recommended reimbursement with conditions, including that its total cost not exceed that of immunoglobulin after the first 6 months. The second NICE draft guidance, open for consultation from 03 November 2026 to 23 November 2026, states that efgartigimod should not be used to treat progressive or relapsing active CIDP in adults after corticosteroids or immunoglobulins, with publication expected on 24 February 2027. A model from a US integrated delivery network perspective projected a total budget impact of $45,996,708, a 35.5% increase, from 10% uptake of efgartigimod alfa in year 1 among an expected 708 immunoglobulin-treated individuals with CIDP in a hypothetical 25-million-member health plan. A Markov model of 5 years of treatment estimated an incremental cost per QALY gained of $687,287 for intravenous immunoglobulin compared with corticosteroids. The company assumes an immunoglobulin price per patient of approximately $150,000 per year and an average biologic net price per patient of approximately $700,000 per year in the US CIDP market.

Source: [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1); [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2); [NICE ID6409 project information (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11508); [Mallick et al. (2025)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002929.html); [Blackhouse et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2903512/); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-4.1-2"></a>

#### CDA-AMC reimbursement recommendation for efgartigimod alfa injection in CIDP: cost-effectiveness and budget impact

> “Final recommendation: Reimburse with conditions”
> “Treatment costs: At the submitted price of $19,750.00 per 5 mL single-dose prefilled syringe, the annual cost of efgartigimod alfa injection is expected to be $1,030,527 per patient, based on the Health Canada–recommended dosage.”
> “Cost of efgartigimod alfa injection versus relevant comparators: Efgartigimod alfa injection is predicted to be associated with higher costs to the health care system than Ig (incremental costs = $6,405,231 per patient), primarily driven by increased costs associated with drug acquisition.”
> “Key findings of the economic evaluation: Based on the submitted evidence using the sponsor’s cost-utility analysis, the CDA-AMC base-case analysis estimated that the incremental cost-effectiveness ratio (ICER) for efgartigimod alfa injection in CIDP was $1,872,111 per QALY gained when compared with Ig.”
> “The cost-effectiveness of efgartigimod alfa injection versus off-label comparators such as corticosteroids, PLEX, immunosuppressives, and rituximab remains unknown.”
> “Anticipated budget impact: CDA-AMC estimated that by year 3 of reimbursement, 2,525 patients would be eligible for treatment with efgartigimod alfa injection, of whom 379 would be expected to receive efgartigimod alfa injection.”
> “The estimated incremental budget impact of reimbursing efgartigimod alfa injection is predicted to be approximately $691 million over the first 3 years, with an expected expenditure of $692 million on efgartigimod alfa injection.”
> “After the first 6 months of treatment, Vyvgart SC will only be covered if there is clinical stability in symptoms using at least 1 approved assessment tool and if the total cost of Vyvgart SC does not exceed the total cost of Ig treatment.”

Source: [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1)

<a id="topic-4.1-3"></a>

#### CDA-AMC economic review of the sponsor's cost-utility model for efgartigimod alfa injection in CIDP

> “The sponsor submitted a cost-utility analysis to estimate the cost-effectiveness of efgartigimod alfa from the perspective of a public health care payer in Canada over a lifetime horizon (55 years).”
> “In the sponsor’s base case, efgartigimod alfa was associated with incremental costs of $6,542,660 and 4.40 incremental QALYs relative to Ig.”
> “This resulted in an incremental cost-effectiveness ratio (ICER) of $1,488,146 per QALY gained.”
> “The model structure, which was based on aINCAT score, may not adequately reflect the management of CIDP in clinical practice and does not represent homogenous health states.”
> “The sponsor assumed the cost of $100.00 per mg based on an INESSS publication.”
> “This increase in health care spending results from higher drug acquisition costs associated with efgartigimod alfa (an additional $6,525,798 per patient).”
> “Approximately 87% of the predicted incremental benefit was accrued on the basis of extrapolation.”

Source: [CDA-AMC efgartigimod alfa reimbursement review (2026)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0894r/3193?inline=1)

<a id="topic-4.1-4"></a>

#### NICE draft guidance on efgartigimod for CIDP (ID6409): recommendation and model structure

> “Efgartigimod should not be used to treat progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) in adults after corticosteroids or immunoglobulins.”
> “The list price of efgartigimod is £15,307.47 for a pre-filled 5-ml syringe containing 1,000 mg of efgartigimod (200 mg per ml; excluding VAT, sourced from company submission).”
> “The company presented a Markov model with time-varying transition probabilities. The health states were defined based on both disease severity and whether the disease was active or in remission.”
> “The company’s model had a lifetime horizon (45 years) and a 6-monthly cycle.”
> “The committee was aware that immunoglobulins are not recommended by NICE and are likely to be highly cost-ineffective treatments. It noted that the company’s model estimated a very high cost per person (over £1.5 million) over the model time horizon.”
> “The exact cost-effectiveness estimates cannot be reported here because of confidential discounts. The company’s base-case ICER using some of the committee’s preferred assumptions was substantially above the range normally considered to be a cost-effective use of NHS resources.”

Source: [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2)

<a id="topic-4.1-5"></a>

#### NICE appraisal of efgartigimod for CIDP (ID6409): status and schedule

> “Expected publication date: 24 February 2027”
> “Draft guidance: 2: 03 November 2026 - 23 November 2026”
> “Committee meeting: 3: 17 December 2026”

Source: [NICE ID6409 project information (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11508)

<a id="topic-4.1-6"></a>

#### US cost per responder of IVIG versus subcutaneous efgartigimod

> “A cost per responder analysis compared Vyvgart hytrulo with Panzyga administered at standard (1 g/kg) and higher (2 g/kg) maintenance doses over 6- and 12-month time horizons.”
> “At 12 months, costs were $190,026, $402,301, and $698,583, respectively.”
> “At 12 months, cost per responder was $256,792 for Panzyga 1 g/kg, $473,295 for Panzyga 2 g/kg, and $1,455,382 for Vyvgart hytrulo.”
> “While no head-to-head clinical trial data were available, differences in trial design and responder definitions between studies may affect comparability.”

Source: [Muley et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42764727/)

<a id="topic-4.1-7"></a>

#### US budget impact of adding efgartigimod alfa for patients receiving immunoglobulin

> “A model was developed to project, from a US integrated delivery network perspective, the costs expected with introducing efgartigimod alfa for CIDP.”
> “For a hypothetical 25-million-member health plan, the analysis estimated, based on prevalence of disease and IG treatment, an expected 708 CIDP patients treated with IG.”
> “Assuming a 10% uptake of efgartigimod alfa in year 1 drawing patient share proportionally from IVIG and SCIG yielded a total projected budget impact of $45,996,708, a 35.5% increase.”

Source: [Mallick et al. (2025)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002929.html)

<a id="topic-4.1-8"></a>

#### Cost-utility of IVIG compared with corticosteroids in Canada

> “A markov model was used to evaluate the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for CIDP.”
> “The incremental cost per QALY gained of IVIG was estimated to be $687,287.”
> “The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG.”
> “Conclusions Based on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP.”

Source: [Blackhouse et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2903512/)

<a id="topic-4.1-9"></a>

#### Cost-utility of IVIG plus corticosteroids in steroid-resistant CIDP in Thailand

> “A Markov model was constructed to estimate the lifetime costs and outcomes for IVIG plus corticosteroids in comparison with immunosuppressants plus corticosteroids in steroid-resistant CIDP patients from a societal perspective.”
> “In the base-case, the incremental costs and quality-adjusted life years (QALYs) of IVIG plus corticosteroids versus immunosuppressants plus corticosteroids were US$2112.02 and 1.263 QALYs, respectively, resulting in an incremental cost-effectiveness ratio (ICER) of US$1672.71 per QALY gained.”

Source: [Bamrungsawad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27113227/)

<a id="topic-4.1-10"></a>

#### Company market assumptions for claseprubart in CIDP

> “The US CIDP market offers substantial growth potential given high unmet need and limitations of current standard of care”
> “Komodo claims data 2013-2025, adjusted to account for 70% capture of real-world patient counts for biologic treated patients, adjusted to account for 27% misdiagnosed.”
> “Assumes Ig price per patient of ~$150,000 per year and average biologic net price per patient of ~$700,000 per year.”
> “~40,000 (~5% CAGR)”
> “CIDP Opportunity for Complement in 2035”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-4.1-11"></a>

#### Cost-utility of intravenous immunoglobulin compared with prednisolone in a European crossover trial

> “Patients were recruited to a double-blind randomized crossover trial from nine European centres and received either prednisolone or IVIg during the first 6-week treatment period on which the economic evaluation was based.”
> “The main outcome measure in the economic evaluation was the number of quality adjusted life years (QALYs) gained, with change in a 11-point disability scale used to measure clinical outcomes.”
> “The cost difference between the two treatments was estimated to be euro 3754 over the 6-week period.”
> “Using a net-benefit approach it was shown that the probability of IVIg being cost-effective in comparison with prednisolone was 0.5 or above (i.e. was more likely to be cost-effective than cost-ineffective) only if one QALY was valued at over euro 250 000.”
> “The cost-effectiveness of IVIg is greatly affected by the price of IVIg and the amount administered.”

Source: [McCrone et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14641514/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
